

## DAFTAR PUSTAKA

- Albert RK, Schuller JL, dan COPD Clinical Research Network. Macrolide Antibiotics and the Risk of Cardiac Arrhythmias. *Am J Respir Crit Care Med.* 2014 May 15; 189(10) 1173-1180.
- Antoniou CK, Dilaveris P, Manolakou P, Galanagos S, Magkas N, Gatzoulis K, dan Tousoulis D. QT Prolongation And Malignant Arrhythmia: How Serious A Problem?. *European Cardiology.* 2017; 12(2).
- Armahizer MJ, Seybert AL, Smithburger PL, dan Kane-Gill SL. Drug-Drug Interactions Contributing to QT Prolongation in Cardiac Intensive Care Units. *J Crit Care.* 2013 Jun; 28(3) 243-249.
- Bennett PB, Yazawa K, Makita N, dan George AL. Molecular Mechanism for an Inherited Cardiac Arrhythmia. *Nature.* 1995 Aug 24; 376(6542) 683-685.
- Berul CI. 2021. *Acquired Long QT Syndrome: Definitions, Causes, and Pathophysiology.* US: UpToDate Inc.
- Boyce MJ, Baisley KJ, dan Warrington SJ. Pharmacokinetic Interaction between Domperidone and Ketoconazole Leads to QT Prolongation in Healthy Volunteers: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study. *Br J Clin Pharmacol.* 2012 Mar; 73(3) 411-421.
- Brown JD, Lim LL, dan Koning S. Voriconazole Associated Torsades de Pointes in Two Adults Patients with Haematological Malignancies. *Med Mycol Case Rep.* 2014 Apr; 4 23-25.
- Camm JA, Malik M, dan Yap YG. 2008. *Acquired Long QT Syndrome.* London: John Wiley & Sons. Cardiology Foundation. *Circulation* 2010; 121: 1047.
- Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Losifescu DV, Smoller JW, dan Perlis RH. QT Interval and Antidepressant Use: a Cross Sectional Study of Electronic Health Records. *BMJ.* 2013; 346: 288-99.

- Catelya LG, Tjahjono CT, dan Hanafi A. Levofloxacin and Drug-Induced Long QT Syndrome (diLQTS): The Incidence and How to Prevent It. *IOP Conference Series: Earth and Environmental Science*. 2020. Volume 441, Issue 1, pp. 012190.
- Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, dan Marty J. Prolongation of QTc Interval After Postoperative Nausea and Vomiting Treatment by Droperidol or Ondansetron. *Anesthesiology*. 2005 Jun; 102 (6) 1094-1100.
- Charbit B, Alvarez JC, Dasque E, Abe E, Demolis JL, Funck-Brentano C. Droperidol and Ondansetron-Induced QT Interval Prolongation: A Clinical Drug Interaction Study. *Anesthesiology*. 2008 Aug; 109(2) 206-212.
- Claassen S dan Zunkler BJ. Comparison of the Effects of Metoclopramide and Domperidone on HERG Channels. *Pharmacology*. 2005 Apr; 74(1) 31-36.
- Couture L, Nash JA, dan Turgeon J. The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart. *Pharmacol Rev*. 2006 Jun; 58(2) 244-258.
- Cubeddu LX. Drug-Induced Inhibition and Trafficking Disruption of Ion Channels: Pathogenesis of QT Abnormalities and Drug-Induced Fatal Arrhythmias. *Curr Cardiol Rev*. 2016; 12(2) 141-154.
- De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, dan Hoes AW. In-Hospital Cardiac Arrest is Associated with Use of Non-Antiarrhythmic QTc-Prolonging Drugs. *Br J Clin Pharmacol*. 2007 Feb; 63(2) 216-223.
- De Ponti F, Poluzzi E, Cavalli A, Recanatini M, dan Montanaro N. Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes: an Overview. *Drug Saf*. 2002; 25: 263.
- Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, dan Zareba W. Prevention of Torsade de Pointes in Hospital

- Settings: a Scientific Statement from the American Heart Association and the American College of Cardiology Foundation. *Circulation*. 2010. 121(8): 1047-60.
- Durdagi S, Subbotina J, Lees-Miller J, Guo J, Duff HJ, dan Noskov SY. Insights into the Molecular Mechanism of HERG1 Channel Activation and Blockade by Drugs. *Curr Med Chem*. 2010. 17(30) 3514-3532.
- FDA. 2020. *Drug Development and Drug Interactions Table of Substrates, Inhibitors, and Inducers*. <https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers> diakses pada tanggal 31 Mei 2021.
- Ferrari R. Writing Narrative Style Literatur Reviews. *Medical Writing*. 2015. 24 (4): 230-235.
- Ficker E, Obejero-Pas CA, Zhao S, dan Brown AM. The Binding Sites for Channel Blockers that Rescue Misprocessed Human Long QT Syndrome Type 2 Ether-A-Go-Go Related Gene (hERG) Mutations. *J Biol Chem*. 2002 Feb 15; 277(7) 4989-4998.
- Ficker E, Dennis AT, Wang L, dan Brown AM. Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel HERG. *Circ Res*. 2003 Jun 27; 92(12) e87-100.
- Ficker E, Kuryshev YA, Dennis AT, Obejero-Pas C, Wang L, Hawryluk P, Wible BA, dan Brown AM. Mechanism of Arcenid-Induced Prolongation of Cardiac Repolarization. *Mol Pharmacol*. 2004 Jul; 66(1) 33-44.
- Freeman BD, Dixon DJ, Coopersmith CM, Zehnauer BA, dan Buchman TG. Pharmacoepidemiology of QT-Interval Prolonging Drug Administration in Critically Ill Patients. *Pharmacoepidemiol Drug Saf*. 2008 Oct; 17(10) 971-981.
- Frommeyer G dan Eckardt L. Drug-Induced Proarrhythmia: Risk Factors and Electrophysiological Mechanisms. *Nat Rev Cardiol*. 2016 Jan; 12(1) 36-47.

- Giudicessi JR, Ackerman MJ, dan Camilleri M. Cardiovascular Safety of Prokinetic Agents: A Focus on Drug-Induced Arrhythmias. *Neurogastroenterol Motil*. 2018 Feb 14; 30(6) e13302.
- Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, dan Ackerman MJ. Institution-Wide QT Alert System identifies Patients with a High Risk of Mortality. *Mayo Clin Proc*. 2013 Apr; 88(4) 315-325.
- Hinder M. Pharmacodynamic Drug-Drug Interactions in Drug Discovery and Evaluation: Methods in Clinical Pharmacology. *Springer*. 2011. 367-376.
- Hohnloser SH, van de Loo A, Baedeker F. Efficacy and Proarrhythmic Hazards of Pharmacologic Cardioversion of Atrial Fibrillation: Prospective Comparison of Sotalol versus Quinidine. *J Am Coll Cardiol*. 1995. 26:852–858.
- Hume JR dan Grant AO. Agents used in cardiac arrhythmias. In: Katzung BG, ed. *Basic and clinical pharmacology*. 10th ed. Boston: McGraw Hill; 2015. p. 211-35.
- Isbister GK, Calver L, van Gorp F, Stokes B, dan Page CB. Inter-rater Reliability of Manual QT Measurement and Prediction of Abnormal QT, HR Pairs. *Clin Toxicol (Phila)*. 2009. 47: 884–8.
- Isbister GK & Page CB. Drug Induced QT Prolongation: The Measurement and Assessment of the QT Interval in Clinical Practice. *British journal of clinical pharmacology*. 2013. 76(1):48-57.
- Justo D dan Zeltser D. Torsade de Pointes Induced by Systemic Antifungal Agents: Lessons from a Retrospective Analysis of Published Case Reports. *Mycoses*. 2006 Nov; 49(6) 463-470.
- Kannankeril P dan Roden DM. Drug-Induced Long QT and Torsades de Pointes: Recent Advances. *Curr Opin Cardiol*. 2007 Jan; 22(1) 39-43.
- Kannankeril P, Roden DM, dan Darbar D. Drug-Induced Long QT Syndrome. *Pharmacol Rev*. 2010. 62: 760-781.

- Kasamaki Y, Ozawa Y, Ohta M, Sezai A, Yamaki T, Kaneko M, Watanabe I, Hirayama A, dan Nakayama T. Automated Versus Manual Measurement of the QT Interval and Corrected QT interval. *Ann Noninvasive Electrocardiol.* 2011. 16:156– 164.
- Kemenkes RI. 2019. *Formularium Nasional*. Jakarta: Kemenkes RI.
- Khan IA. Long QT Syndrome: Diagnosis and Management. *Am Heart J* 2002; 143:7.
- Kudaibergenova M, Perissinotti LL, dan Noskov SY. Lipid Roles in HERG Function and Interactions with Drugs. *Neurosci Lett.* 2019 May 01; 700 70-77.
- Kuryshv YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W, Rampe D. Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking. *J Pharmacol Exp Ther.* 2005 Jan; 312(1) 316-323.
- Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, dan Bor DH. Timing of New Black Box Warnings and Withdrawals for Prescription Medications. *JAMA.* 2002;287.
- Lee JH, Park YH, Kim JT, Kim CS, dan Kim HS. The Effect of Sevoflurane and Ondansetron on QT Interval and Transmural Dispersion of Repolarization in Children. *Paediatr Anaesth.* 2014 Apr; 24(4) 421-425.
- Lee W, Windley MJ, Vandenberg JJ, dan Hill AP. In Vitro and In Silico Risk Assessment in Acquired Long QT Syndrome: The Devil is in the Details. *Front Physiol.* 2017 Nov 16; 8 934.
- Lefevre G, Carpenter P, Soupart C, Schmidli H, McClean M, Stypincki D. Pharmacokinetics and Electrocardiographic Pharmacodynamics of Artemether-Lumefantrine (Riamet) with Concomitant Administration of Ketoconazole in Healthy Subjects. *Br J Clin Pharmacol.* 2002 Nov; 54(5) 485-492.

- Lexi-Interact™ online, <http://www.uptodate.com/cr/lsq/interact/frameset.jsp> diakses pada 24 Agustus 2021.
- Lu Y, Mahaut-Smith MP, Varghese A, Huang CL, Kemp PR, dan Vandenberg JI. Effects of Premature Stimulation on HERG K(+) Channels. *J Physiol* (Lond). 2001 Dec 15; 537(Pt3) 843-851.
- Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, dan Lin RZ. Suppression of Phosphoinositide-3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome. *Sci Transl Med*. 2012 Apr 25; 4(131) 131ra50.
- Malik MCA. Evaluation of Drug-Induced QT Interval Prolongation: Implications for Drug Approval and Labelling. *Drug Saf*. 2001. 24:323–351.
- Mann D, Zipes D, Libby P, dan Bonow R. 2014. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th Edition*. Philadelphia: Elsevier.
- McKechnie K, Froese AI. Ventricular Tachycardia After Ondansetron Administration in a Child with Undiagnosed Long QT Syndrome. *Can J Anesth*. 2010; 57: 453-7.
- Merck Manual. 2021. *Drugs by Name, Generic and Brand*. <https://www.merckmanuals.com/professional/resources/brand-names-of-some-commonly-used-drugs> diakses pada 29 Juni 2021.
- Michaud V, Frappier M, Dumas MC, dan Turgeon J. Metabolic Activity and mRNA Levels of Human Cardiac CYP450 Involved in Drug Metabolism. *PLoS ONE*. 2010 Dec 14; 5(12) e15666.
- Min-Shu Wu, Ling Gao, Xiao-Hui Cai, Guang-Ji Wang. Determination of Domperidone in Human Plasma by LC-MS and its Pharmacokinetics in Healthy Chinese Volunteers. *Acta Pharmacologica Sinica*. 2016.

- Mitcheson JS, Chen J, Lin M, Culberson C, dan Sanguinetti MC. A Structural Basis for Drug-Induced Long QT Syndrome. *Proc Natl Acad Sci USA*. 2000 Oct 24; 97(22) 12329-12333.
- Nachimuthu S, Assar MD, dan Schussler JM. Drug-Induced QT Interval Prolongation: Mechanisms and Clinical Management. *Ther Adv Drug Saf*. 2012. 3(5) 241-253.
- Nafrialdi, Kurniawan TG, Setiawati A, dan Makmun LH. QT Interval Prolongation Associated with Amiodarone Use in Cipto Mangunkusumo Hospital, Jakarta. *Acta Medica Indonesiana*. 2014. Vol. 46 No. 4.
- Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, Acquaro G, dan Priori SG. Evidence for a Cardiac Ion Channel Mutation Underlying Drug-Induced QT Prolongation and Life-Threatening Arrhythmias. *J Cardiovasc Electrophysiol* 2000; 11.
- Nemeroff CB, Preskorn SH, dan Devane CL. Antidepressant Drug-Drug Interactions: Clinical Relevance and Risk Management. *CNS Spectr*. 2007 May 01; 12(5 Suppl 7) 1-13.
- Nogawa H, Kawai T, Yajima M, Miura M, Ogawa T, dan Murakami K. Effects of Probucol, a Typical HERG Expression Inhibitor, on In Vivo QT Interval Prolongation Conscious Dogs. *Eur J Pharmacol*. 2013 Nov 15; 720(1-3) 29-37.
- Novita NF dan Destiani DP. Interaksi Obat Terhadap Perpanjangan Interval QT. *Farmaka*. 2020. Vol. 18 No. 1.
- Nuryati. 2017. *Farmakologi*. Jakarta: Kemenkes RI.
- Paine MF, Wagner DA, Hoffmaster KA, dan Watkins PB. Cytochrome P450 3A4 and P-glycoprotein Mediate the Interaction between an oral Erythromycin Breath Test and Rifampin. *Clin Pharmacol Ther*. 2002 Nov; 72(5) 524-535.

- Passman R dan Kadish A. Polymorphic Ventricular Tachycardia, Long Q-T Syndrome, and Torsades de Pointes. *Med Clin North Am.* 2001; 85:321.
- Pearson EC dan Woosley RL. QT Prolongation and Torsades de Pointes Among Methadone Users: Reports to the FDA Spontaneous Reporting System. *Pharmacoepidemiol Drug Saf.* 2005 Nov; 14(11) 747-753.
- Perissinotti LL, De Biase PM, Guo J, Yang PC, Lee MC, Clancy CE, Duff HJ, dan Noskov SY. Determinants of Isoform-Specific Gating Kinetics of HERG1 Channel: Combined Experimental and Simulation Study. *Front Physiol.* 2018 Apr 12; 9 207.
- Pham CP, de Feiter PW, van der Kuy PH, dan van Mook WN. Long QTc Interval and Torsade de Pointes Caused by Fluconazole. *Ann Pharmacother.* 2006 Aug; 40(7-8) 1456-1461.
- Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, dan Drew BJ. How Many Patients Need QT Interval Monitoring in Critical Care Unites? Preliminary Report of the QT in Practice Study. *J Electrocardiol.* 2010 Dec; 43(6) 572-576.
- Postema PG, De Jong JS, Van der Bilt IA, dan Wilde AA,. Accurate Electrocardiographic Assessment of the QT Interval: Teach the Tangent. *Heart Rhythm.* 2008. 5:1015–1018.
- Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, January CT. Drug-Induced Long QT Syndrome: hERG K<sup>+</sup> Channel Block and Disruption of Protein Trafficking by Fluoxetine and Norfluoxetine. *Br J Pharmacol.* 2006 Nov; 149(5) 481-489.
- Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, dan Stein CM. Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes. *N Engl J Med.* 2004 Sep 09; 351(11) 1089-1096.



- Roden DM. Taking the "Idio" Out of "Idiosyncratic": Predicting Torsades de Pointes. *Pacing Clin Electrophysiol*. 1998; 21:1029.
- Roden DM. Keep The QT Interval: It is a Reliable Predictor of Ventricular Arrhythmias. *Heart Rhythm*. 2008 Aug; 5(8).
- Roden DM. Predicting Drug-Induce QT Prolongation and Torsades de Pointes. *J Physiol (Lond)*. 2016 May 01; 594(9) 2459-2468.
- Roden DM. A Current Understanding of Drug-Induced QT Prolongation and Its Implications for Anticancer Therapy. *Cardiovasc Res*. 2019 Apr 15; 115(5) 895-903.
- Sala M, Vicentini A, Brambilla P, Montomoli C, Jogja JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, dan De Ferrari GM. QT Interval Prolongation Related to Psychoactive Drug Treatment: A Comparison of Monotherapy Versus Polytherapy. *Ann Gen Psychiatry*. 2005 Jan 25; 4(1) 1.
- Sanguinetti MC dan Jurkiewicz NK. Two Components of Cardiac Delayed Rectifier K<sup>+</sup> Current. Differential Sensitivity to Block by Class III Antiarrhythmic Agents. *J Gen Physiol*. 1990 Jul; 96(1) 195-215.
- Schwartz PJ dan Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. *J Am Coll Cardiol*. 2016 Apr 05; 67 (13) 1639-1650.
- Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL, dan Goldstein JSA. A Common Polymorphism Associated with Antibiotic-Induced Cardiac Arrhythmia. *Proc Natl Acad Sci U S A* 2000; 97.
- Shaffer D, Singer S, Korvick J, dan Honig P. Concomitant Risk Factors in Reports of Torsade de Pointes Associated in Macrolide Use: Review of the United States Food and Drug Administration Adverse Event Reporting System. *Clin Infect Dis*. 2002 Jul 15; 35(2) 197-200.

- Sharma ND, Rosman HS, Padhi ID, dan Tisdale JE. Torsades de Pointes Associated with Intravenous Haloperidol in Critically ill Patients. *Am J Cardiol.* 1998 Jan 15; 81(2) 238-240.
- Simard C, Michaud V, Gibbs B, Masse R, Lessard E, dan Turgeon J. Identification of the Cytochrome P450 Enzymes Involved in the Metabolism of Domperidone. *Xenobiotica.* 2004 Dec; 34(11-12) 1013-1023.
- Smith PL, Baukrowitz T, dan Yellen G. The Inward Rectification Mechanism of the HERG Cardiac Potassium Channel. *Nature.* 1996 Feb 29; 379 (6568) 833-836.
- Sordillo PP, Sordillo DC, dan Helson L. Review: The Prolonged QT Interval: Role of Pro-Inflammatory Cytokines, Reactive Oxygen Species, and the ceramide and Sphingosine-1 Phosphate Pathways. *In Vivo.* 2015 Dec; 29(6) 619-636.
- Soyka LF, Wirtz C, dan Spangenberg RB. Clinical Safety Profile of Sotalol in Patients with Arrhythmias. *Am J Cardiol.* 1990 65:74A–81A.
- Straus SMJM, Bleumink GS, Dieleman JP, Van der Lei J, Jong GW, Kingma JH, Sturkenboom MCJM, dan Stricker BHC. Antipsychotics and the Risk of Sudden Cardiac Death. *Arch Intern Med.* 2004. Jun 28;164(12):1293-7.
- Stringer J, Welsh C, dan Tommasello A. Methadone-Associated Q-T Interval Prolongation and Torsades de Pointes. *Am J Health Syst Pharm.* 2009 May 01; 66(9) 825-833.
- Takemasa H, Nagatomo T, Abe H, Kawakami K, Igarashi T, Tsurugi T, Kabashima N, Tamura M, Okazaki M, Delisle BP, January CT, Otsuji Y. Coexistence of HERG Current Block and Disruption of Protein Trafficking in Ketoconazole-Induced Long QT Syndrome. *Br J Pharmacol.* 2008 Feb; 153(3) 439-447.
- Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, dan Camm AJ. Dofetilide in

Patients with Congestive Heart Failure and Left Ventricular Dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. *N Engl J Med*. 1999. 341:857–865.

Trinkley KE, Page RL, Lien H, Yamanouye, dan Tisdale J. QT Interval Prolongation and the Risk of Torsades de Pointes: Essentials for Clinicians. *CMRO*. 2013. 1-8.

Tschida SJ, Guay DRP, Straka RJ, Hoey LL, Johanning R, dan Vance-Bryan K. QTc-Interval Prolongation Associated with Slow Intravenous Erythromycin Lactobionate Infusions in Critically Ill Patients: A Prospective Evaluation and Review of the Literature. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 1996 Jul 08.

US Department of Health and Human Services. 2010. *Common Terminology Criteria for Adverse Events (CTCAE)*, 4.03 ed. National Institute of Health, National Cancer Institute.

Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, dan Hill AP. HERG K(+) Channels: Structure, Function, and Clinical Significance. *Physiol Rev*. 2012 Jul; 92(3) 1393-1478.

Vandenberg JI, Perozo E, dan Allen TW. Towards a Structural View of Drug Binding to HERG K<sup>+</sup> Channels. *Trends Pharmacol Sci*. 2017 Jul 12; 38(10) 899-907.

Wacker S dan Noskov SY. Performance of Machine Learning Algorithms for Qualitative and Quantitative Prediction Drug Blockade of HERG1 Channel. *Comput Toxicol*. 2018 May; 6 55-63.

Wang L, Wible BA, Wan X, dan Ficker E. Cardiac Glycosides as Novel Inhibitors of Human Ether-A-Go-Go-Related Gene Channel Trafficking. *J Pharmacol Exp Ther*. 2007 Feb; 320(2) 525-534.

Wang W dan MacKinnon R. Cryo-EM Structure of the Open Human Ether-A-Go-Go-Related K<sup>+</sup> Channel HERG. *Cell*. 2017 Apr 20; 169(3) 422-430.e10.

- Wiśniowska B, Tylutki Z, Wyszogrodzka G, dan Polak S. Drug-Drug Interactions and QT Prolongation as a Commonly Assessed Cardiac Effect – Comprehensive Overview of Clinical Trials. *BMC Pharmacol Toxicol*. 2016 Mar 10; 17 12.
- Woosley RL, Heise CW, dan Romero KA. *QTdrugs List*. www.Crediblemeds.org diakses pada tanggal 18 Januari 2021. Accession Date, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755.
- Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL, dan Roden M. Allelic Variants in Long-QT Disease Genes in Patients with Drug-Associated Torsades de Pointes. *Circulation* 2002; 105.
- Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, Roden DM. Screening for Acute IKr Block is Insufficient to Detect Torsades de Pointes Liability: Role of Late Sodium Current. *Circulation*. 2014 Jul 15; 130(3) 224-234.
- Yang T, Meoli DF, Moslehi J, dan Roden DM. Inhibition of the  $\alpha$ -Subunit of Phosphoinositide-3-Kinase in Heart Increases Late Sodium Current and is Arrhythmogenic. *J Pharmacol Exp Ther*. 2018 Mar 21; 365(3) 460-466.
- Yap YG dan Camm AJ. Drug Induced QT Prolongation and Torsades de Pointes. *Heart*. 2003 Nov; 89(11) 1363-1372.
- Yeung KS dan Meanwell NA. Inhibition of HERG Channel Trafficking: An Under-explored Mechanism for Drug-Induced QT Prolongation. *Chem Med Chem*. 2008 Oct; 3(10) 1501-1502.
- Zeuli JD, Wilson JW, dan Estes LL. Effect of Combined Fluoroquinolone and Azole Use on QT Prolongation in Hematology Patients. *Antimicrob Agents Chemother*. 2013 Mar; 57(3) 1121-1127.